FDA Approves Second Humira Biosimilar, Cyltezo

Adalimumab-adbm Cyltezo, from Boehringer Ingelheim, is approved for multiple indications including treatment of adults with moderate-to-severe active rheumatoid arthritis.
FDA Approvals

http://ift.tt/2xk2CyB